Spyre Therapeutics share price logo

Spyre Therapeutics

NASDAQ: SYRE

Mid Cap

$106.83

-0.96

(-0.89%)

Live

as on

Spyre Therapeutics Stock Performance

as on August 22, 2026 at 6:16 am IST

  • Day's Low

    Day's High

    $105.71
    $109.81
    downward going graph

    1.05%

    Downside

    2.79%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $14.51
    $108.14
    downward going graph

    86.42%

    Downside

    1.23%

    Upside

    downward going graph

Spyre Therapeutics share price movements today

Previous Close
$107.79
Open
$109.00
Volume
566.5K
Market Cap
$9.0B
Day's Low - High
$105.71 - $109.81
52 Week Low - High
$14.51 - $108.14

Spyre Therapeutics Historical Returns

1 Month Return
+ 3.39 %
3 Month Return
+ 38.32 %
1 Year Return
+ 511.39 %
3 Year Return
0 %
5 Year Return
0 %

Spyre Therapeutics Stock Fundamentals & Key Indicators

Check Spyre Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$9.0B

EPS (TTM)

-2.8285

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-1.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-207.8M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-22.98%

Spyre Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Spyre Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$9.0BNANA0.00%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$25.3B-84.24%-7.98-12.57%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Spyre Therapeutics Stock including INR - Dollar returns

The Spyre Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Spyre Therapeutics investment value today

Current value as on today

₹6,90,853

Returns

₹5,90,853

(+590.85%)

Returns from Spyre Therapeutics Stock

₹5,30,265 (+530.27%)

Dollar Impact

₹60,587 (+60.59%)

Analyst Recommendation on Spyre Therapeutics Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.85714285714286% of analysts recommend a 'BUY' rating for Spyre Therapeutics. Average target price of $124.71

Spyre Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Spyre Therapeutics.

What analysts predicted

14.34%UPSIDE

Target Price

$124.71

Current Price

$106.83

Analyzed by

14 Analysts

Target

$124.71

Spyre Therapeutics target price $124.71, a slight upside of 14.34% compared to current price of $106.83. According to 14 analysts rating.

Indian Investors' Interest in Spyre Therapeutics Stock

Search interest for Spyre Therapeutics Stock has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:17% versus previous 30 day period

Spyre Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
90
-
-
Gross Profit
-
-
-
-
-
-
-45
45
-
-
Operating Income
-47
-44
-55
-61
-53
-41
-56
-57
-45
-41
EBITDA
-43
-38
-69
-56
-44
-51
-11
-62
-75
-36
Interest Expense
-
-
-
21
-
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-43
-38
-69
-56
-44
-36
-11
-62
-69
-36
Income Tax Expense
0
-
0
0
0
-
-
0
-
-
Net Income
-43
-38
-69
-56
-44
-36
-11
-62
-69
-36
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-69.10%
0.00%
0.00%

Spyre Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
4
5
3
-
-
18
2
0
0
-
Gross Profit
4
5
3
0
-1
18
2
0
0
-171
Operating Income
-21
-27
-45
-80
-81
-65
-84
-242
-208
-209
EBITDA
-21
-27
-45
-77
-79
-64
-81
-242
-207
-209
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
0
0
1
1
0
-
-
Income Before Tax
-21
-27
-44
-78
-80
-65
-83
-338
-207
-155
Income Tax Expense
-
-
-
-
0
0
0
0
0
0
Net Income
-21
-27
-44
-78
-80
-65
-83
-338
-208
-155
Net Profit Margin
-468.84%
-523.27%
-1140.64%
0.00%
0.00%
-351.14%
-3598.75%
-38238.15%
-23478.33%
0.00%

Spyre Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-38
-69
-56
-44
-36
-11
-62
-69
-36
Operating Cash Flow
-62
-29
-37
-40
-46
-37
-44
-57
-69
Investing Cash Flow
-120
42
-170
0
78
24
-247
56
-297
Financing Cash Flow
0
12
225
0
0
-4
312
12
432
Change in Cash
-182
26
17
-40
33
-16
20
11
64

Spyre Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-27
-44
-78
-80
-65
-83
-338
-208
-155
Operating Cash Flow
-24
-32
-65
-75
-53
-80
-99
-157
-169
Investing Cash Flow
-22
-15
-1
-7
-22
57
-
-353
-143
Financing Cash Flow
12
57
65
154
1
42
361
410
309
Change in Cash
-34
9
-3
71
-74
19
152
-99
-3

Mutual Funds that own Spyre Therapeutics Stock

Check out the Mutual Funds with significant holdings in Spyre Therapeutics.

Funds
Holdings
Shares Held
Fidelity Mt. Vernon Street Trust
4.005889%
3532143
VANGUARD INDEX FUNDS
3.378942%
2979341
SMALLCAP World Fund Inc
2.736293%
2412693
Fidelity Securities Fund
1.929323%
1701157
Fidelity Select Portfolios
1.521941%
1341953

Global Institutional Holdings in Spyre Therapeutics

Funds
Holdings
Vanguard
6.3%
Peter Harwin
4.56%
Joseph Edelman
4.29%
iShares
4.05%
Richard Driehaus
3.17%

Spyre Therapeutics News & Key Events

  • img

    Today's Timeline - 13 October

    Tue, 01:31 AM

    -

    Spyre Therapeutics announces proposed public offering of common stock and pre-funded warrants.

    Tue, 06:38 AM

    -

    Spyre Therapeutics prices public offering at $18.50 per share, aiming to raise $275 million.

Insights on Spyre Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, SYRE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, SYRE stock has moved up by 542.4%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, SYRE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 5 quarters, 168.0K → 90.49M (in $), with an average increase of 54.8% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -69.00M → -36.19M (in $), with an average increase of 90.6% per quarter

About Spyre Therapeutics

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
OrganisationSpyre Therapeutics
HeadquartersBuilding 23, Waltham, MA, United States, 02453
IndustryBiotechnology
CEODr. Cameron Turtle DPHIL, Ph.D.
E-voting on sharesClick here to vote

Key Management of Spyre Therapeutics

Name

Title

Mr. Eric McIntyre

Senior Vice President of Finance & Investor Relations

Mr. James Myers

Senior Vice President of Quality & Compliance

Mr. Scott L. Burrows

Chief Financial Officer

Dr. Janet Gunzner-Toste M.B.A., Ph.D.

Senior Vice President of Operations

Dr. Sheldon Sloan M.B.E., M.D.

Chief Medical Officer

Mr. Brian Connolly

Chief Technical Officer

Dr. Justin LaFountaine Ph.D.

Senior Vice President of Corporate Development

Ms. Melissa Cooper

Senior Vice President of People

Dr. Cameron Turtle DPHIL, Ph.D.

CEO & Director

Ms. Heidy Abreu King-Jones J.D., L.L.M.

Chief Legal Officer & Corporate Secretary

FAQs

What is Spyre Therapeutics share price today?

Spyre Therapeutics share price today is $106.83 as on . Spyre Therapeutics share today touched a day high of $109.81 and a low of $105.71.

What is the 52 week high and 52 week low for Spyre Therapeutics share?

Spyre Therapeutics share touched a 52 week high of $108.14 on and a 52 week low of $14.51 on . Spyre Therapeutics stock price today i.e. is trending at $106.83,which is 1.21% down from its 52 week high and 636.50% up from its 52 week low.

What is Spyre Therapeutics's market capitalisation today?

Spyre Therapeutics market capitalisation is $0.01T as on .

How to invest in Spyre Therapeutics Stock (SYRE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Spyre Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Spyre Therapeutics Shares that will get you 0.0140 shares as per Spyre Therapeutics share price of $106.83 per share as on August 22, 2026 at 12:46 am IST.

What is the minimum amount required to buy Spyre Therapeutics Stock (SYRE) from India?

Indian investors can start investing in Spyre Therapeutics (SYRE) shares with as little as ₹95.685 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.85 in Spyre Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Spyre Therapeutics share’s latest price of $106.83 as on August 22, 2026 at 12:46 am IST, you will get 0.0936 shares of Spyre Therapeutics. Learn more about fractional shares .